var data={"title":"Staphylococcus lugdunensis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Staphylococcus lugdunensis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/contributors\" class=\"contributor contributor_credentials\">Vivian H Chu, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 29, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Staphylococcus lugdunensis</em> is a coagulase-negative staphylococcus (CoNS). Like other CoNS, <em>S. lugdunensis </em>in humans ranges from a harmless skin commensal to a life-threatening pathogen (as with infective endocarditis). Unlike other CoNS, however, <em>S. lugdunensis </em>can cause severe disease reminiscent of the virulent infections frequently attributable to <em>Staphylococcus aureus </em>[<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/1\" class=\"abstract_t\">1</a>]. In addition, most <em>S. lugdunensis</em> isolates remain susceptible to a large number of antimicrobial agents.</p><p><em>S. lugdunensis</em> was first described in 1988 and was distinguished from other coagulase-negative staphylococcal species via DNA-relatedness studies based on 11 clinical strains. The new species was named after Lyon, the French city where the organism was first isolated (Lugdunum, the Latin name of Lyon) [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/2\" class=\"abstract_t\">2</a>]. <em>S. lugdunensis</em> is unique among CoNS because of its propensity for causing aggressive native valve infective endocarditis and its susceptibility to a vast array of antimicrobial agents.</p><p>The microbiology, clinical features, and treatment of <em>S. lugdunensis</em> infections will be reviewed here. Other issues related to coagulase-negative staphylococci are discussed in detail separately.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. lugdunensis</em> infections in humans range from harmless skin colonization to invasive infection. The majority of infections are related to skin and soft tissue, the bloodstream, and prosthetic devices.</p><p>The frequency of <em>S. lugdunensis</em> infection is probably underappreciated, since many clinical laboratories do not routinely speciate coagulase-negative staphylococci [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/3,4\" class=\"abstract_t\">3,4</a>]. Among 494 coagulase-negative staphylococcal isolates from a clinical setting, <em>S. lugdunensis</em> accounted for 3 percent of isolates [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/3\" class=\"abstract_t\">3</a>]. Unlike <em>Staphylococcus epidermidis</em>, in general, <em>S. lugdunensis</em> should be presumed to be a true pathogen. Among 229 <em>S. lugdunensis</em> clinical isolates in one series, only 15 percent were considered contaminants or colonizing organisms [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. lugdunensis</em> is a gram-positive, catalase-positive, coagulase-negative coccus. It is a nonmotile, facultative anaerobe that may demonstrate hemolysis on blood agar [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/6\" class=\"abstract_t\">6</a>]. Colonies of <em>S. lugdunensis</em> can appear unpigmented, cream-colored, or pale yellow to golden after five days of incubation [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/2,6\" class=\"abstract_t\">2,6</a>].</p><p>Slide and rapid latex agglutination tests are used by many laboratories to distinguish coagulase-negative from coagulase-positive staphylococci (<em>S. aureus</em>). However, the performance characteristics of these tests for <em>S. lugdunensis</em> are variable, and the presence of clumping factor can lead to false identification of <em>S. aureus</em> [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/7-9\" class=\"abstract_t\">7-9</a>]. For this reason, the tube coagulase test should be used to distinguish <em>S. lugdunensis</em> as a coagulase-negative <em>Staphylococcus</em> instead of a coagulase-positive <em>Staphylococcus</em>.</p><p>Biochemical testing for pyrrolidonyl arylamidase and ornithine decarboxylase activity can be used to distinguish <em>S. lugdunensis</em> from other coagulase-negative staphylococci (CoNS). Identification of <em>S. lugdunensis</em> can also be accomplished through commercially available phenotypic identification systems (commercial kits and automated systems) [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/8,10\" class=\"abstract_t\">8,10</a>] and newer methods such as matrix-assisted desorption ionization&ndash;time of flight mass spectrometry (MALDI-TOF MS) [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/11\" class=\"abstract_t\">11</a>]. In addition, <em>S. lugdunensis</em> can be identified by molecular methods using gene targets [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/12-15\" class=\"abstract_t\">12-15</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Antibiotic susceptibility</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. lugdunensis</em> isolates are unique among the coagulase-negative staphylococci by virtue of their susceptibility to a wide range of antimicrobials. In vitro testing of clinical <em>S. lugdunensis</em> isolates has demonstrated antimicrobial susceptibility to <a href=\"topic.htm?path=cefazolin-drug-information\" class=\"drug drug_general\">cefazolin</a>, <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>, <a href=\"topic.htm?path=moxifloxacin-drug-information\" class=\"drug drug_general\">moxifloxacin</a>, <a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">nafcillin</a>, <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>, and <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/9\" class=\"abstract_t\">9</a>]. <em>S. lugdunensis</em> resistance to beta-lactams, macrolides, and aminoglycosides is uncommon [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/6,16,17\" class=\"abstract_t\">6,16,17</a>].</p><p>Penicillin resistance in <em>S. lugdunensis</em> was reported to be as low as &lt;4 percent in the 1990s [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/18\" class=\"abstract_t\">18</a>]; however, penicillin resistance appears to be increasing with estimates of 12 to 27 percent in the 2000s [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/7,8,19,20\" class=\"abstract_t\">7,8,19,20</a>]. One study in 2010 noted a resistance rate of 45 percent [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Methicillin resistance in <em>S. lugdunensis</em> has been noted in a few case reports, and presence of <em>mecA</em> (the gene encoding methicillin resistance in <em>S. aureus</em>) in <em>S. lugdunensis</em> is uncommon (reported in 3 to 5 percent of <em>S. lugdunensis</em> isolates) [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/4,7,21,22\" class=\"abstract_t\">4,7,21,22</a>]. The <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a> breakpoint for <em>S. lugdunensis</em> was modified in 2005 to more precisely reflect the presence of <em>mecA</em>. <em>S. lugdunensis</em> isolates with an oxacillin minimum inhibitory concentration (MIC) &le;2 <span class=\"nowrap\">mcg/mL</span> are defined as susceptible; those with oxacillin MICs of &ge;4 <span class=\"nowrap\">mcg/mL</span> are defined as resistant [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/23\" class=\"abstract_t\">23</a>]. This is in contrast with other coagulase-negative staphylococci for which the breakpoint for oxacillin susceptible is &le;0.25 <span class=\"nowrap\">mcg/mL</span> and for oxacillin resistant is &ge;0.5 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/24\" class=\"abstract_t\">24</a>].</p><p><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> tolerance has been described in <em>S. lugdunensis</em>, meaning that the bacteria are able to survive in the presence of an antibiotic to which it is considered susceptible by MIC. This was demonstrated in 93 percent of <em>S. lugdunensis</em> isolates tested using an minimal bactericidal concentration <span class=\"nowrap\">(MBC)/MIC</span> ratio of &ge;32 [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/9\" class=\"abstract_t\">9</a>] and 46 percent (6 of 13) of isolates tested by the killing curve method [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/25\" class=\"abstract_t\">25</a>]. The clinical significance of vancomycin tolerance is uncertain, although these findings raise important concerns regarding selection of antimicrobial therapy.</p><p>The presence of biofilm appears to influence the efficacy of antimicrobial agents in vitro [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/26-28\" class=\"abstract_t\">26-28</a>]. A study of <em>S. lugdunensis</em> antimicrobial susceptibility demonstrated that planktonic <em>S. lugdunensis</em> isolates were susceptible to all 10 antistaphylococcal agents tested, while those in biofilms were highly resistant. Biofilm formation was increased in the presence of <a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">nafcillin</a> by 93 percent of organisms, while biofilm formation was decreased in the presence of <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> and <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>. <a href=\"topic.htm?path=moxifloxacin-drug-information\" class=\"drug drug_general\">Moxifloxacin</a> was the only antibiotic with activity against the <em>S. lugdunensis</em> organisms in biofilm; 73 percent of the biofilm isolates were susceptible [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/9\" class=\"abstract_t\">9</a>]. The clinical significance of biofilm and antimicrobial susceptibility is uncertain.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adherence factors allowing <em>S. lugdunensis</em> to bind to host tissues and implantable materials are thought to play a major role in the pathogenesis of <em>S. lugdunensis</em> infections. Von Willebrand factor-binding protein allows interaction between the organism and clotting during vascular injury [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/29\" class=\"abstract_t\">29</a>], and fibrinogen-binding protein allows <em>S. lugdunensis</em> to bind host matrix proteins.</p><p>Biofilm formation plays a major role in the pathogenesis of <em>S. lugdunensis</em> infections: it permits attachment of the organism on implantable devices and provides protection from antibiotics and host immunity [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/30\" class=\"abstract_t\">30</a>]. The biofilm of <em>S. lugdunensis</em> is composed of proteins rather than polysaccharide (which is a major component of biofilm produced by other organisms) [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/31\" class=\"abstract_t\">31</a>]. The clinical significance of a protein-based biofilm matrix is uncertain, although the presence of biofilm appears to modify the efficacy of antimicrobial agents in vitro. (See <a href=\"#H4\" class=\"local\">'Antibiotic susceptibility'</a> above.)</p><p>The role of biofilms in the pathogenesis of infection due to coagulase-negative staphylococci is discussed in further detail separately. (See <a href=\"topic.htm?path=infection-due-to-coagulase-negative-staphylococci-epidemiology-microbiology-and-pathogenesis#H6\" class=\"medical medical_review\">&quot;Infection due to coagulase-negative staphylococci: Epidemiology, microbiology, and pathogenesis&quot;, section on 'Biofilm'</a>.)</p><p>The pathogenesis of <em>S. lugdunensis</em> has not been associated with toxin production.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The frequency of <em>S. lugdunensis</em> infection is probably underappreciated, since some clinical laboratories do not routinely speciate coagulase-negative staphylococci (CoNS). Virulent infection due to CoNS should prompt speciation; unlike <em>S. epidermidis</em>, <em>S. lugdunensis</em> should generally be presumed to be a true pathogen.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Skin and soft tissue</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most clinical infections due to <em>S. lugdunensis</em> are soft tissue infections (80 percent of cases) [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p>Several studies suggest that <em>S. lugdunensis</em> tends to colonize and cause infection below the waist [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/19,32-34\" class=\"abstract_t\">19,32-34</a>]. There are reports of <em>S. lugdunensis</em> infective endocarditis (IE) occurring in the setting of prostate cancer [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/6\" class=\"abstract_t\">6</a>], vasectomy [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/35\" class=\"abstract_t\">35</a>], and perineal lesions [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/36-38\" class=\"abstract_t\">36-38</a>], all suggesting that <em>S. lugdunensis</em> has a predilection for colonization and infection of the perineal area. Among 38 patients with <em>S. lugdunensis</em> infection in one series, 73 percent of infections (mostly soft tissue abscesses) occurred below the waist [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/19\" class=\"abstract_t\">19</a>].</p><p>In a series of 140 patients, the prevalence of inguinal colonization with <em>S. lugdunensis</em> was about 20 percent (among both men and women) [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/39\" class=\"abstract_t\">39</a>]. Inguinal colonization of the inguinal area appears to predispose to infection after invasive procedures, and shaving this area prior to surgery has been associated with an increased rate of <em>S. lugdunensis</em> infections [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/39\" class=\"abstract_t\">39</a>].</p><p>The breast is another important site of <em>S. lugdunensis</em> infection. Breast abscesses (both spontaneous and postoperative infections) have been reported in nonlactating women [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/40\" class=\"abstract_t\">40</a>]. In one review, breast abscesses accounted for five of seven <em>S. lugdunensis</em> infections that occurred above the waist [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/19\" class=\"abstract_t\">19</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Endocarditis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. lugdunensis</em> endocarditis is an aggressive infection that affects native valves with greater frequency than prosthetic valves, in contrast to other coagulase-negative staphylococci [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/41,42\" class=\"abstract_t\">41,42</a>].</p><p><em>S. lugdunensis</em> native valve endocarditis is typically community acquired and associated with a high rate of complications and death. In a review of 53 patients with native valve <em>S. lugdunensis</em> endocarditis, the rate of heart failure was 45 percent, periannular abscess 19 percent, embolization 30 percent, and death 42 percent [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/43\" class=\"abstract_t\">43</a>]. While high rates of heart failure and valvular complications are also seen in the setting of endocarditis due to other coagulase-negative staphylococci (mostly <em>S. epidermidis</em>), the mortality rate of <em>S. lugdunensis</em> endocarditis rivals that of <em>S. aureus</em> [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/42,44-47\" class=\"abstract_t\">42,44-47</a>]. (See <a href=\"topic.htm?path=epidemiology-risk-factors-and-microbiology-of-infective-endocarditis\" class=\"medical medical_review\">&quot;Epidemiology, risk factors, and microbiology of infective endocarditis&quot;</a>.)</p><p><em>S. lugdunensis</em> also causes prosthetic valve endocarditis. In a review of nine cases of <em>S. lugdunensis</em> prosthetic valve endocarditis, the rate of heart failure was 22 percent, periannular abscess 66 percent, embolization 11 percent, and death 78 percent [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/43\" class=\"abstract_t\">43</a>]. The majority of these infections are late onset. Among six cases of <em>S. lugdunensis</em> prosthetic valve endocarditis, one infection occurred within six months of valve implantation; the rest occurred between 2 and 13 years after the original valve implantation [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/16\" class=\"abstract_t\">16</a>].</p><p><em>S. lugdunensis</em> <span class=\"nowrap\">pacemaker/implantable</span> cardioverter defibrillator (ICD) lead endocarditis has also been described. Among seven patients managed with both hardware removal and antibiotic therapy, one patient died [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/43\" class=\"abstract_t\">43</a>]. Small colony variants of <em>S. lugdunensis</em> (pathogenic forms that facilitate persistent and recurrent infection) have been reported in the setting of pacemaker retention and persistent infection [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/48\" class=\"abstract_t\">48</a>].</p><p>Reasons for the high mortality observed in cases of <em>S. lugdunensis</em> endocarditis are unclear. Nevertheless, evidence suggests that the prognosis for <em>S. lugdunensis</em> endocarditis has improved. Among 20 cases of <em>S. lugdunensis</em> endocarditis reported up to 1993, the mortality was 70 percent; among 28 cases reported after 1993, mortality was 18 percent [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/16,41\" class=\"abstract_t\">16,41</a>]. The mortality observed for the later cases is more consistent with the mortality associated with coagulase-negative staphylococcal (mostly <em>S. epidermidis</em>) native valve endocarditis [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/44\" class=\"abstract_t\">44</a>].</p><p>It is unclear why the late cases were associated with an improved prognosis. Possible explanations include a higher rate of surgery for cases after 1993 than cases before (64 versus 35 percent), earlier diagnosis of <em>S. lugdunensis</em> endocarditis due to more frequent speciation of coagulase-negative staphylococci, and a higher proportion of native valve cases after 1993 than before (89 versus 70 percent) [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Bacteremia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. lugdunensis</em> non-endocarditis (non-IE) bacteremia is a less aggressive infection than <em>S. lugdunensis</em> endocarditis. Among 21 episodes of <em>S. lugdunensis</em> bacteremia in one series, six appeared to be clinically significant cases of non-IE bacteremia. Five of these patients had a hemodialysis or tunneled intravenous catheter; none experienced suppurative complications or death [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/49\" class=\"abstract_t\">49</a>]. Similar outcomes were observed in another series of 15 cases of non-IE <em>S. lugdunensis</em> bacteremia; a catheter or foreign device was identified in 73 percent of patients, and there were no complications related to the bacteremia [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/50\" class=\"abstract_t\">50</a>].</p><p>Thus, the data suggest that there is a dichotomy for <em>S. lugdunensis</em> bacteremia. Non-IE bacteremia tends to be healthcare associated (ie, nosocomial or associated with foreign devices) and has a relatively good prognosis; bacteremia with endocarditis is often community acquired and associated with an aggressive course [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/51\" class=\"abstract_t\">51</a>]. However, the data are subject to selection bias, since coagulase-negative staphylococci is not speciated in many institutions.</p><p>Single positive blood cultures for <em>S. lugdunensis</em> should not be dismissed as culture contaminants; clinicians should carefully consider clinical presentation and risk factors for infection. In one study including 29 patients with a single positive blood culture for <em>S. lugdunensis</em>, the result was clinically significant in 45 percent of cases [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/52\" class=\"abstract_t\">52</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Prosthetic devices</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cases of <em>S. lugdunensis</em> prosthetic joint infection have been described in detail [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/53-55\" class=\"abstract_t\">53-55</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>S. lugdunensis</em> infection was reported two years after a total hip arthroplasty in an otherwise healthy patient [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/53\" class=\"abstract_t\">53</a>]. This was treated with abscess drainage, intraarticular teicoplanin injections, and oral <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> for three months [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/53\" class=\"abstract_t\">53</a>]. The patient remained asymptomatic up to six years of follow-up.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>S. lugdunensis</em> infection of knee arthroplasty was reported in a patient on <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> four years after total knee arthroplasty. This patient was treated with resection arthroplasty, six weeks of <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a>, and delayed reimplantation with no relapse after 10 months follow-up [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/54\" class=\"abstract_t\">54</a>]. Other cases of <em>S. lugdunensis</em> knee arthroplasty infections with clinical cure have been reported [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/54,55\" class=\"abstract_t\">54,55</a>].</p><p/><p>In one study including 28 episodes of <em>S. lugdunensis</em> knee and hip prosthetic joint infections, prosthetic knee infection was more common than prosthetic hip infection (89 versus 11 percent), and an underlying urogenital abnormality was observed in nearly one-third of patients [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/56\" class=\"abstract_t\">56</a>].</p><p><em>S. lugdunensis</em> has also been reported in association with ventriculoperitoneal shunts and external ventriculostomy drains [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/57,58\" class=\"abstract_t\">57,58</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Other infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of other infections due to <em>S. lugdunensis</em> have been described:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Septic arthritis after arthroscopic anterior cruciate ligament revision has been described [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/59\" class=\"abstract_t\">59</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteomyelitis of the thoracic and lumbar spine has been reported in the setting of advanced age and immunosuppression [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/55,60-62\" class=\"abstract_t\">55,60-62</a>]. Osteomyelitis of the ear canal has been noted in a patient with noninsulin-dependent diabetes [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/63\" class=\"abstract_t\">63</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute postoperative endophthalmitis (mean of 7.6 days after cataract surgery) was observed among five patients in one series. Treatment included intravenous, intravitreal, topical antibiotics, and pars plana vitrectomy (four patients). Despite aggressive treatment, outcomes were poor for three out of the five patients [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/64\" class=\"abstract_t\">64</a>]. (See <a href=\"topic.htm?path=bacterial-endophthalmitis\" class=\"medical medical_review\">&quot;Bacterial endophthalmitis&quot;</a>.)</p><p/><p>Cases of endometritis [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/65\" class=\"abstract_t\">65</a>], acute suppurative lymphadenitis [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/66\" class=\"abstract_t\">66</a>], psoas abscess [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/67\" class=\"abstract_t\">67</a>], urinary tract infection [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/68,69\" class=\"abstract_t\">68,69</a>], and peritonitis with exit site infection [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/70\" class=\"abstract_t\">70</a>] have also been described.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of infection due to <em>S. lugdunensis</em> should be guided by the results of antibiotic susceptibility testing. Most isolates are susceptible to penicillin, and this is the drug of choice for treatment of infection if susceptibility permits. Isolates possessing beta-lactamase (fewer than one-quarter) are resistant to penicillin [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/20\" class=\"abstract_t\">20</a>]. Almost all of <em>S. lugdunensis</em> isolates are susceptible to <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a>, and the presence of <em>mecA</em> is uncommon [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/4,7,21,22\" class=\"abstract_t\">4,7,21,22</a>].</p><p><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> is an appropriate alternative agent if resistance or sensitivity precludes use of beta-lactam agents.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Skin and soft tissue</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to antibiotic selection for treatment of <em>S. lugdunensis</em> skin and soft tissue infections is as outlined in the preceding section. Abscesses should be drained if possible. The duration of therapy depends on individual circumstances but, in general, consists of one to two weeks of therapy; the clinical response to therapy should guide antibiotic duration. Deep-seated infections may warrant parenteral therapy initially, though therapy may be completed with oral agents depending on individual circumstances.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Endocarditis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of native valve infectious endocarditis should consist of six weeks of parenteral beta-lactam therapy or <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> (depending on susceptibility testing and beta-lactam hypersensitivity). Limited data suggest comparable mortality outcomes with monotherapy and combination therapy for native valve infective endocarditis (IE) [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/43\" class=\"abstract_t\">43</a>].</p><p>Treatment of prosthetic valve IE should consist of combination therapy including a beta-lactam (or <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>) with an aminoglycoside and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>. The <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> should be administered for the first two weeks of therapy; the beta-lactam (or vancomycin) and rifampin should be continued for six weeks. This approach is extrapolated from the <em>S. aureus</em> literature. (See <a href=\"topic.htm?path=antimicrobial-therapy-of-prosthetic-valve-endocarditis\" class=\"medical medical_review\">&quot;Antimicrobial therapy of prosthetic valve endocarditis&quot;</a>.)</p><p>Surgery must be considered given the frequency of valvular compromise in the setting of <em>S. lugdunensis</em> IE. In a review of 10 patients with <em>S. lugdunensis</em> IE, all patients with left-sided IE had serious complications; surgery was required in more than half of cases [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/43\" class=\"abstract_t\">43</a>]. Predictors of surgery included age &lt;50, absence of significant comorbidity, aortic valve involvement, and periannular abscess. (See <a href=\"topic.htm?path=surgery-for-left-sided-native-valve-infective-endocarditis\" class=\"medical medical_review\">&quot;Surgery for left-sided native valve infective endocarditis&quot;</a>.)</p><p>The treatment of <em>S. lugdunensis</em> pacemaker endocarditis includes antibiotic therapy as well as removal of the pacer system. The mortality with this infection is low if the pacemaker and leads are removed [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/43\" class=\"abstract_t\">43</a>]. (See <a href=\"topic.htm?path=infections-involving-cardiac-implantable-electronic-devices\" class=\"medical medical_review\">&quot;Infections involving cardiac implantable electronic devices&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Bacteremia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bacteremia without endocarditis (often related to an intravascular catheter) appears to have a good prognosis [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/50\" class=\"abstract_t\">50</a>]. Nevertheless, given the potential for <em>S. lugdunensis</em> to be associated with aggressive IE, bacteremia due to <em>S. lugdunensis</em> should be treated similarly to <em>S. aureus</em> [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/71\" class=\"abstract_t\">71</a>]. Therefore, for intravascular catheter-related <em>S. lugdunensis</em> bacteremia, the catheter should be removed, followed by 14 days of antibiotics, provided that all of the following are applicable: the patient is not diabetic or immunosuppressed; there is no prosthetic material, thrombophlebitis, IE, evidence of metastatic infection; and the patient's fever and bacteremia resolve within 72 hours after initiation of appropriate antibiotic therapy [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/71\" class=\"abstract_t\">71</a>]. The approach to antibiotic selection is outlined above. (See <a href=\"#H12\" class=\"local\">'Treatment'</a> above.)</p><p>The outcome of retaining the intravascular catheter is uncertain but would likely require a longer course of antibiotics [<a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/71\" class=\"abstract_t\">71</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Prosthetic devices</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of prosthetic joint infections generally consists of two-stage arthroplasty and at least six weeks of antibiotics. Antibiotic selection for treatment of infection due to <em>S. lugdunensis</em> is outlined in the preceding section. (See <a href=\"#H12\" class=\"local\">'Treatment'</a> above.)</p><p>The long-term outcome of <em>S. lugdunensis</em> prosthetic joint infection is unknown. Although some case reports describe definitive treatment of <em>S. lugdunensis</em> prosthetic joint infections without prosthesis removal, these data must be interpreted with caution since coagulase-negative staphylococcal infections can be indolent with delayed presentation.</p><p>Additional considerations for treatment of prosthetic joint infections are discussed in detail separately. (See <a href=\"topic.htm?path=prosthetic-joint-infection-treatment\" class=\"medical medical_review\">&quot;Prosthetic joint infection: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Other infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antibiotic selection for treatment of infection due to <em>S. lugdunensis</em> is outlined in the preceding section. (See <a href=\"#H12\" class=\"local\">'Treatment'</a> above.)</p><p>General approaches to septic arthritis, vertebral osteomyelitis, and other types of infection that can be caused by <em>S. lugdunensis</em> are discussed in detail separately. (See <a href=\"topic.htm?path=vertebral-osteomyelitis-and-discitis-in-adults\" class=\"medical medical_review\">&quot;Vertebral osteomyelitis and discitis in adults&quot;</a> and <a href=\"topic.htm?path=septic-arthritis-in-adults\" class=\"medical medical_review\">&quot;Septic arthritis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In humans, the significance of <em>Staphylococcus lugdunensis</em> ranges from a harmless skin commensal to a life-threatening pathogen (such as in the case of infective endocarditis). Unlike other coagulase-negative staphylococci (CoNS), however, <em>S. lugdunensis</em> can cause severe disease reminiscent of the virulent infections frequently attributable to <em>Staphylococcus aureus</em>. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The frequency of <em>S. lugdunensis</em> infection is probably underappreciated, since many clinical laboratories do not routinely speciate coagulase-negative staphylococci. Virulent infection due to CoNS should prompt speciation; unlike <em>S. epidermidis</em>, <em>S. lugdunensis</em> should generally be presumed to be a true pathogen. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>S. lugdunensis</em> is a gram-positive, catalase-positive, coagulase-negative coccus. <em>S. lugdunensis</em> isolates are unique among the coagulase-negative staphylococci by virtue of their susceptibility to a wide range of antimicrobials. (See <a href=\"#H3\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Biofilm formation plays a major role in the pathogenesis of <em>S. lugdunensis</em> infection; it provides protection from antibiotics and host immunity and permits attachment of the organism on implantable devices. The presence of biofilm appears to modify the efficacy of antimicrobial agents in vitro. (See <a href=\"#H5\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical infections due to <em>S. lugdunensis</em> include soft tissue infections, endocarditis, bacteremia, prosthetic device infections, osteomyelitis, and others. Several studies suggest that <em>S. lugdunensis</em> tends to colonize and cause infection below the waist. <em>S. lugdunensis</em> endocarditis is an aggressive infection that affects native valves with greater frequency than prosthetic valves. (See <a href=\"#H6\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of infection due to <em>S. lugdunensis</em> should be guided by the results of antibiotic susceptibility testing. We recommend treatment of <em>S. lugdunensis</em> with penicillin (if susceptibility and individual circumstances permit) (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). Appropriate alternative agents include other beta-lactam drugs and <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>. The duration of therapy depends on the site of infection. (See <a href=\"#H12\" class=\"local\">'Treatment'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/1\" class=\"nounderline abstract_t\">Frank KL, Del Pozo JL, Patel R. From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev 2008; 21:111.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/2\" class=\"nounderline abstract_t\">Freney J, Brun Y, Bes M, et al. Staphylococcus lugdunensis sp nov and Staphylococcus schleiferi sp nov, two species from human clinical specimens. Int J Syst Bacteriol 1988; 38:168.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/3\" class=\"nounderline abstract_t\">Gatermann SG, Koschinski T, Friedrich S. Distribution and expression of macrolide resistance genes in coagulase-negative staphylococci. Clin Microbiol Infect 2007; 13:777.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/4\" class=\"nounderline abstract_t\">Kleiner E, Monk AB, Archer GL, Forbes BA. Clinical significance of Staphylococcus lugdunensis isolated from routine cultures. Clin Infect Dis 2010; 51:801.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/5\" class=\"nounderline abstract_t\">Herchline TE, Ayers LW. Occurrence of Staphylococcus lugdunensis in consecutive clinical cultures and relationship of isolation to infection. J Clin Microbiol 1991; 29:419.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/6\" class=\"nounderline abstract_t\">Fleurette J, B&egrave;s M, Brun Y, et al. Clinical isolates of Staphylococcus lugdunensis and S. schleiferi: bacteriological characteristics and susceptibility to antimicrobial agents. Res Microbiol 1989; 140:107.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/7\" class=\"nounderline abstract_t\">Tan TY, Ng SY, He J. Microbiological characteristics, presumptive identification, and antibiotic susceptibilities of Staphylococcus lugdunensis. J Clin Microbiol 2008; 46:2393.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/8\" class=\"nounderline abstract_t\">Mateo M, Maestre JR, Aguilar L, et al. Genotypic versus phenotypic characterization, with respect to susceptibility and identification, of 17 clinical isolates of Staphylococcus lugdunensis. J Antimicrob Chemother 2005; 56:287.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/9\" class=\"nounderline abstract_t\">Frank KL, Reichert EJ, Piper KE, Patel R. In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob Agents Chemother 2007; 51:888.</a></li><li class=\"breakAll\">Carroll K, Weinstein M. 2007. Manual and automated systems for detection and identification of microorganisms. In: Manual of clinical microbiology, 9th ed, Murray PR, Baron EJ, Jorgensen JH, et al (Eds), ASM Press, Washington, DC 2009. Vol 1, p.192.</li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/11\" class=\"nounderline abstract_t\">Loonen AJ, Jansz AR, Bergland JN, et al. Comparative study using phenotypic, genotypic, and proteomics methods for identification of coagulase-negative staphylococci. J Clin Microbiol 2012; 50:1437.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/12\" class=\"nounderline abstract_t\">Petti CA, Simmon KE, Miro JM, et al. Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective. J Clin Microbiol 2008; 46:1780.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/13\" class=\"nounderline abstract_t\">Martineau F, Picard FJ, Ke D, et al. Development of a PCR assay for identification of staphylococci at genus and species levels. J Clin Microbiol 2001; 39:2541.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/14\" class=\"nounderline abstract_t\">Poyart C, Quesne G, Boumaila C, Trieu-Cuot P. Rapid and accurate species-level identification of coagulase-negative staphylococci by using the sodA gene as a target. J Clin Microbiol 2001; 39:4296.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/15\" class=\"nounderline abstract_t\">Goh SH, Potter S, Wood JO, et al. HSP60 gene sequences as universal targets for microbial species identification: studies with coagulase-negative staphylococci. J Clin Microbiol 1996; 34:818.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/16\" class=\"nounderline abstract_t\">Vandenesch F, Etienne J, Reverdy ME, Eykyn SJ. Endocarditis due to Staphylococcus lugdunensis: report of 11 cases and review. Clin Infect Dis 1993; 17:871.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/17\" class=\"nounderline abstract_t\">Higaki S, Kitagawa T, Morohashi M, Yamagishi T. Distribution and antimicrobial susceptibility of coagulase-negative staphylococci from skin lesions. J Int Med Res 1999; 27:191.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/18\" class=\"nounderline abstract_t\">Paterson DL, Nuttall N. Serious infections due to Staphylococcus lugdunensis. Aust N Z J Med 1997; 27:591.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/19\" class=\"nounderline abstract_t\">Hellbacher C, T&ouml;rnqvist E, S&ouml;derquist B. Staphylococcus lugdunensis: clinical spectrum, antibiotic susceptibility, and phenotypic and genotypic patterns of 39 isolates. Clin Microbiol Infect 2006; 12:43.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/20\" class=\"nounderline abstract_t\">Herchline TE, Barnishan J, Ayers LW, Fass RJ. Penicillinase production and in vitro susceptibilities of Staphylococcus lugdunensis. Antimicrob Agents Chemother 1990; 34:2434.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/21\" class=\"nounderline abstract_t\">Becker K, Pagnier I, Schuhen B, et al. Does nasal cocolonization by methicillin-resistant coagulase-negative staphylococci and methicillin-susceptible Staphylococcus aureus strains occur frequently enough to represent a risk of false-positive methicillin-resistant S. aureus determinations by molecular methods? J Clin Microbiol 2006; 44:229.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/22\" class=\"nounderline abstract_t\">Tee WS, Soh SY, Lin R, Loo LH. Staphylococcus lugdunensis carrying the mecA gene causes catheter-associated bloodstream infection in premature neonate. J Clin Microbiol 2003; 41:519.</a></li><li class=\"breakAll\">CLSI. 2005. Performance standards for antimicrobial susceptibility testing: Fifteenth informational supplement. CLSI/NCCLS document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA. 2005.</li><li class=\"breakAll\">NCCLS. 1999. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement M100-S9. NCCLS, Wayne, PA. 1999.</li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/25\" class=\"nounderline abstract_t\">Bourgeois I, Pestel-Caron M, Lemeland JF, et al. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci. Antimicrob Agents Chemother 2007; 51:740.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/26\" class=\"nounderline abstract_t\">G&ouml;tz F. Staphylococcus and biofilms. Mol Microbiol 2002; 43:1367.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/27\" class=\"nounderline abstract_t\">O'Gara JP. ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. FEMS Microbiol Lett 2007; 270:179.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/28\" class=\"nounderline abstract_t\">Pareja J, Gupta K, Koziel H. The toxic shock syndrome and Staphylococcus lugdunensis bacteremia. Ann Intern Med 1998; 128:603.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/29\" class=\"nounderline abstract_t\">Liesenborghs L, Peetermans M, Claes J, et al. Shear-Resistant Binding to von Willebrand Factor Allows Staphylococcus lugdunensis to Adhere to the Cardiac Valves and Initiate Endocarditis. J Infect Dis 2016; 213:1148.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/30\" class=\"nounderline abstract_t\">Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/31\" class=\"nounderline abstract_t\">Frank KL, Patel R. Poly-N-acetylglucosamine is not a major component of the extracellular matrix in biofilms formed by icaADBC-positive Staphylococcus lugdunensis isolates. Infect Immun 2007; 75:4728.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/32\" class=\"nounderline abstract_t\">Tan TY, Ng SY, Ng WX. Clinical significance of coagulase-negative staphylococci recovered from nonsterile sites. J Clin Microbiol 2006; 44:3413.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/33\" class=\"nounderline abstract_t\">Bellamy R, Barkham T. Staphylococcus lugdunensis infection sites: predominance of abscesses in the pelvic girdle region. Clin Infect Dis 2002; 35:E32.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/34\" class=\"nounderline abstract_t\">B&ouml;cher S, T&oslash;nning B, Skov RL, Prag J. Staphylococcus lugdunensis, a common cause of skin and soft tissue infections in the community. J Clin Microbiol 2009; 47:946.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/35\" class=\"nounderline abstract_t\">Fervenza FC, Contreras GE, Garratt KN, Steckelberg JM. Staphylococcus lugdunensis endocarditis: a complication of vasectomy? Mayo Clin Proc 1999; 74:1227.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/36\" class=\"nounderline abstract_t\">Lessing MP, Crook DW, Bowler IC, Gribbin B. Native-valve endocarditis caused by Staphylococcus lugdunensis. QJM 1996; 89:855.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/37\" class=\"nounderline abstract_t\">Patel R, Piper KE, Rouse MS, et al. Frequency of isolation of Staphylococcus lugdunensis among staphylococcal isolates causing endocarditis: a 20-year experience. J Clin Microbiol 2000; 38:4262.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/38\" class=\"nounderline abstract_t\">Polenakovik H, Herchline T, Bacheller C, Bernstein J. Staphylococcus lugdunensis endocarditis after angiography. Mayo Clin Proc 2000; 75:656.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/39\" class=\"nounderline abstract_t\">van der Mee-Marquet N, Achard A, Mereghetti L, et al. Staphylococcus lugdunensis infections: high frequency of inguinal area carriage. J Clin Microbiol 2003; 41:1404.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/40\" class=\"nounderline abstract_t\">Lina B, Vandenesch F, Reverdy ME, et al. Non-puerperal breast infections due to Staphylococcus lugdunensis. Eur J Clin Microbiol Infect Dis 1994; 13:686.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/41\" class=\"nounderline abstract_t\">Seenivasan MH, Yu VL. Staphylococcus lugdunensis endocarditis--the hidden peril of coagulase-negative staphylococcus in blood cultures. Eur J Clin Microbiol Infect Dis 2003; 22:489.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/42\" class=\"nounderline abstract_t\">Liu PY, Huang YF, Tang CW, et al. Staphylococcus lugdunensis infective endocarditis: a literature review and analysis of risk factors. J Microbiol Immunol Infect 2010; 43:478.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/43\" class=\"nounderline abstract_t\">Anguera I, Del R&iacute;o A, Mir&oacute; JM, et al. Staphylococcus lugdunensis infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker lead endocarditis clinical profiles. Heart 2005; 91:e10.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/44\" class=\"nounderline abstract_t\">Chu VH, Woods CW, Miro JM, et al. Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis 2008; 46:232.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/45\" class=\"nounderline abstract_t\">Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/46\" class=\"nounderline abstract_t\">R&oslash;der BL, Wandall DA, Frimodt-M&oslash;ller N, et al. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159:462.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/47\" class=\"nounderline abstract_t\">Watanakunakorn C. Staphylococcus aureus endocarditis at a community teaching hospital, 1980 to 1991. An analysis of 106 cases. Arch Intern Med 1994; 154:2330.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/48\" class=\"nounderline abstract_t\">Seifert H, Oltmanns D, Becker K, et al. Staphylococcus lugdunensis pacemaker-related infection. Emerg Infect Dis 2005; 11:1283.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/49\" class=\"nounderline abstract_t\">Ebright JR, Penugonda N, Brown W. Clinical experience with Staphylococcus lugdunensis bacteremia: a retrospective analysis. Diagn Microbiol Infect Dis 2004; 48:17.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/50\" class=\"nounderline abstract_t\">Zinkernagel AS, Zinkernagel MS, Elzi MV, et al. Significance of Staphylococcus lugdunensis bacteremia: report of 28 cases and review of the literature. Infection 2008; 36:314.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/51\" class=\"nounderline abstract_t\">Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/52\" class=\"nounderline abstract_t\">Fadel HJ, Patel R, Vetter EA, Baddour LM. Clinical significance of a single Staphylococcus lugdunensis-positive blood culture. J Clin Microbiol 2011; 49:1697.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/53\" class=\"nounderline abstract_t\">Sanz&eacute;ni L, Ringberg H. Fistulating periprosthetic Staphylococcus lugdunensis hip infection cured by intra-articular teicoplanin injections--a case report. Acta Orthop Scand 2003; 74:624.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/54\" class=\"nounderline abstract_t\">Sampathkumar P, Osmon DR, Cockerill FR 3rd. Prosthetic joint infection due to Staphylococcus lugdunensis. Mayo Clin Proc 2000; 75:511.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/55\" class=\"nounderline abstract_t\">Weightman NC, Allerton KE, France J. Bone and prosthetic joint infection with Staphylococcus lugdunensis. J Infect 2000; 40:98.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/56\" class=\"nounderline abstract_t\">Shah NB, Osmon DR, Fadel H, et al. Laboratory and clinical characteristics of Staphylococcus lugdunensis prosthetic joint infections. J Clin Microbiol 2010; 48:1600.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/57\" class=\"nounderline abstract_t\">Elliott SP, Yogev R, Shulman ST. Staphylococcus lugdunensis: an emerging cause of ventriculoperitoneal shunt infections. Pediatr Neurosurg 2001; 35:128.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/58\" class=\"nounderline abstract_t\">Spanu T, Rigante D, Tamburrini G, et al. Ventriculitis due to Staphylococcus lugdunensis: two case reports. J Med Case Rep 2008; 2:267.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/59\" class=\"nounderline abstract_t\">Mei-Dan O, Mann G, Steinbacher G, et al. Septic arthritis with Staphylococcus lugdunensis following arthroscopic ACL revision with BPTB allograft. Knee Surg Sports Traumatol Arthrosc 2008; 16:15.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/60\" class=\"nounderline abstract_t\">Murdoch DR, Everts RJ, Chambers ST, Cowan IA. Vertebral osteomyelitis due to Staphylococcus lugdunensis. J Clin Microbiol 1996; 34:993.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/61\" class=\"nounderline abstract_t\">Camacho M, Guis S, Mattei JP, et al. Three-year outcome in a patient with Staphylococcus lugdunensis discitis. Joint Bone Spine 2002; 69:85.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/62\" class=\"nounderline abstract_t\">Greig JM, Wood MJ. Staphylococcus lugdunensis vertebral osteomyelitis. Clin Microbiol Infect 2003; 9:1139.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/63\" class=\"nounderline abstract_t\">Thomas S, Hoy C, Capper R. Osteomyelitis of the ear canal caused by Staphylococcus lugdunensis. J Infect 2006; 53:e227.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/64\" class=\"nounderline abstract_t\">Chiquet C, Pechinot A, Creuzot-Garcher C, et al. Acute postoperative endophthalmitis caused by Staphylococcus lugdunensis. J Clin Microbiol 2007; 45:1673.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/65\" class=\"nounderline abstract_t\">Bello C, Eskandar M, El GR, et al. Staphylococcus lugdunensis endometritis: a case report. West Afr J Med 2007; 26:243.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/66\" class=\"nounderline abstract_t\">Kim JH, Lee JY, Kim HR, et al. Acute lymphadenitis with cellulitis caused by Staphylococcus lugdunensis. Korean J Lab Med 2008; 28:196.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/67\" class=\"nounderline abstract_t\">Hammami BK, Ghorbel H, Abid F, et al. [Psoas abscess of the adult: study of 38 cases]. Tunis Med 2007; 85:631.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/68\" class=\"nounderline abstract_t\">Casanova-Roman M, Sanchez-Porto A, Casanova-Bellido M. Urinary tract infection due to Staphylococcus lugdunensis in a healthy child. Scand J Infect Dis 2004; 36:149.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/69\" class=\"nounderline abstract_t\">Haile DT, Hughes J, Vetter E, et al. Frequency of isolation of Staphylococcus lugdunensis in consecutive urine cultures and relationship to urinary tract infection. J Clin Microbiol 2002; 40:654.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/70\" class=\"nounderline abstract_t\">Schnitzler N, Meilicke R, Conrads G, et al. Staphylococcus lugdunensis: report of a case of peritonitis and an easy-to-perform screening strategy. J Clin Microbiol 1998; 36:812.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-lugdunensis/abstract/71\" class=\"nounderline abstract_t\">Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3155 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H18\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">MICROBIOLOGY</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Antibiotic susceptibility</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">PATHOGENESIS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Skin and soft tissue</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Endocarditis</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Bacteremia</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Prosthetic devices</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Other infections</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">TREATMENT</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Skin and soft tissue</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Endocarditis</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Bacteremia</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Prosthetic devices</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Other infections</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antimicrobial-therapy-of-prosthetic-valve-endocarditis\" class=\"medical medical_review\">Antimicrobial therapy of prosthetic valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-endophthalmitis\" class=\"medical medical_review\">Bacterial endophthalmitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-risk-factors-and-microbiology-of-infective-endocarditis\" class=\"medical medical_review\">Epidemiology, risk factors, and microbiology of infective endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-due-to-coagulase-negative-staphylococci-epidemiology-microbiology-and-pathogenesis\" class=\"medical medical_review\">Infection due to coagulase-negative staphylococci: Epidemiology, microbiology, and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infections-involving-cardiac-implantable-electronic-devices\" class=\"medical medical_review\">Infections involving cardiac implantable electronic devices</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prosthetic-joint-infection-treatment\" class=\"medical medical_review\">Prosthetic joint infection: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=septic-arthritis-in-adults\" class=\"medical medical_review\">Septic arthritis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgery-for-left-sided-native-valve-infective-endocarditis\" class=\"medical medical_review\">Surgery for left-sided native valve infective endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vertebral-osteomyelitis-and-discitis-in-adults\" class=\"medical medical_review\">Vertebral osteomyelitis and discitis in adults</a></li></ul></div></div>","javascript":null}